seed
Stage
1
Investors
About
Fibrocor develops first-in-class therapeutics targeting fibroblast activation to treat genetically-driven fibrotic kidney diseases such as Alport Syndrome and Autosomal Dominant Polycystic Kidney Disease (ADPKD). Their approach is based on biomarker-driven discovery using extensive human fibrosis tissue biobanks.
Explore Fibrocor's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.